Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases
Journal article published in 2014 by
G. Procopio 
,
E. Verzoni,
P. Biondani,
P. Grassi,
I. Testa,
E. Garanzini,
F. De Braud
,
E. Verzoni,
P. Biondani,
P. Grassi,
I. Testa,
E. Garanzini,
F. De Braud
